DLQI as a major criterion for introduction of systemic agents in patients with mild psoriasis

Psoriasis is a skin inflammatory chronic disease with negative physical, psychological and social repercussions for those affected. However, patients suffering from mild disease also complain about negative impact on their quality of life, making it difficult for physicians to choose the best treatment strategy.

[1]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool , 2017, The British journal of dermatology.

[2]  J. Hendriks,et al.  A pilot study on the Psoriasis Area and Severity Index (PASI) for small areas: Presentation and implications of the Low PASI score , 2015, The Journal of dermatological treatment.

[3]  M. Eriksson,et al.  Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI) , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[4]  G. Trajkovic,et al.  Identification of psoriatic patients at risk of high quality of life impairment , 2013, The Journal of dermatology.

[5]  G. Schmid‐Ott,et al.  Perceived relationships between severity of psoriasis symptoms, gender, stigmatization and quality of life , 2013, Journal of the European Academy of Dermatology and Venereology : JEADV.

[6]  G. Nocea,et al.  Validation of a new tool to assess health-related quality of life in psoriasis: the PSO-LIFE questionnaire , 2012, Health and Quality of Life Outcomes.

[7]  M. Otuki,et al.  Patient‐reported outcomes in psoriasis research and practice , 2011, The British journal of dermatology.

[8]  C. Griffiths,et al.  Definition of treatment goals for moderate to severe psoriasis: a European consensus , 2010, Archives of Dermatological Research.

[9]  Jan D Bos,et al.  How good are clinical severity and outcome measures for psoriasis?: quantitative evaluation in a systematic review. , 2010, The Journal of investigative dermatology.

[10]  F. Aubin,et al.  What are the best outcome measures for assessing quality of life in plaque type psoriasis? A systematic review of the literature , 2010, Journal of the European Academy of Dermatology and Venereology : JEADV.

[11]  M. Augustin,et al.  Concordance of the Psoriasis Area and Severity Index (PASI) and patient-reported outcomes in psoriasis treatment. , 2010, European journal of dermatology : EJD.

[12]  W. Sterry,et al.  Do guidelines change the way we treat? Studying prescription behaviour among private practitioners before and after the publication of the German Psoriasis Guidelines , 2009, Archives of Dermatological Research.

[13]  A. Finlay,et al.  Clinical management decisions are related to the impact of psoriasis on patient‐rated quality of life , 2005, The British journal of dermatology.

[14]  D M Reboussin,et al.  Psoriasis causes as much disability as other major medical diseases. , 1999, Journal of the American Academy of Dermatology.

[15]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[16]  T Fredriksson,et al.  Severe psoriasis--oral therapy with a new retinoid. , 1978, Dermatologica.